Olfactory and gustatory impairments in COVID-19 patients: Role in early diagnosis and interferences by concomitant drugs

Br J Clin Pharmacol. 2021 May;87(5):2186-2188. doi: 10.1111/bcp.14634. Epub 2020 Nov 13.

Authors

Sara Ferraro¹, Marco Tuccori^{1

2}, Irma Convertino¹, Giulia Valdiserra¹, Emiliano Cappello¹, Fabrizio Maggi^{3

4}, Corrado Blandizzi^{1

2}, Daniele Focosi⁵

Affiliations

¹ Unit of Pharmacology and Pharmacovigilance, Department of Clinical and Experimental Medicine, University of Pisa, Italy.
² Unit of Adverse Drug Reactions Monitoring, University Hospital of Pisa, Pisa, Italy.
³ Virology Division, Pisa University Hospital, Pisa, Italy.
⁴ Department of Translational Research, University of Pisa, Pisa, Italy.
⁵ North-Western Tuscany Blood Bank, University Hospital of Pisa, Pisa, Italy.

PMID: 33185930
DOI: 10.1111/bcp.14634

No abstract available

Keywords: COVID-19; SARS-CoV-2; adverse drug reactions; ageusia; anosmia; cacosmia; dysgeusia.

MeSH terms

COVID-19 / complications*
Early Diagnosis
Humans
Olfaction Disorders / diagnosis*
Olfaction Disorders / virology
Pharmaceutical Preparations*
Taste Disorders / diagnosis*
Taste Disorders / virology

Substances

Pharmaceutical Preparations